New York, January 9, 2026, 09:22 EST — Premarket
- NEOG up about 0.3% in premarket, after a roughly 32% jump in the prior session
- Company raised fiscal 2026 revenue outlook to $845 million–$855 million
- Investors look for detail on Petrifilm integration and manufacturing moves in the weeks ahead
Neogen Corp shares hovered near $9.74 in premarket trade on Friday, little changed after a sharp rally a day earlier. The stock jumped 31.6% on Thursday to close at $9.71.
The move puts Neogen back on traders’ screens after a long stretch where the company’s story was more about fixes than growth. At this price, the market is not paying for patience.
Chief Executive Mike Nassif said the company has started “the first phase” of a strategic transformation and is trying to stabilize its core business as the industry faces “macro headwinds.” He said Neogen is focused on integrating Petrifilm — part of the former 3M food safety business — and optimizing sample collection manufacturing. Nasdaq
Neogen reported quarterly revenue of $224.7 million for the period ended Nov. 30, down 2.8% from a year earlier. Core revenue growth — which strips out currency swings and discontinued lines — rose 2.9%, while the company posted a net loss of $15.9 million, or 7 cents per share, and adjusted profit of 10 cents per share. It raised fiscal 2026 revenue guidance to $845 million–$855 million and said it expects adjusted EBITDA — a rough measure of operating cash profit — of about $175 million.
The results topped Wall Street estimates, Barron’s reported, citing FactSet. Analysts had been looking for adjusted earnings of 6 cents a share on revenue of about $207.7 million, it said.
Gross margin fell to 47.5% from 49.0% a year earlier, weighed by tariff costs, inventory write-offs and product mix, the company said. Food Safety segment revenue rose 0.8% to $165.6 million, while Animal Safety revenue fell 11.8% to $59.1 million, reflecting the impact of divestitures and discontinued product lines; on a core basis, both segments were roughly flat to up modestly. Neogen ended the quarter with $145.3 million in cash and $800.0 million in debt.
Neogen furnished the earnings release in an SEC filing on Thursday.
But the surge leaves little room for stumbles. Investors will want follow-through in margins and demand once the “clean-up” effects fade, and any slip in the manufacturing work could revive worries about execution.
The next scheduled update comes Jan. 14, when Nassif is due to present at the J.P. Morgan Healthcare Conference at 5:15 p.m. PT.
